Brief: Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist

Valion Bio

12/02/2025 13:34

Feb 12 (Reuters) - Tivic Health Systems  TIVC.O :
    * TIVIC HEALTH ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO PHASE
III
TLR5 AGONIST FROM STATERA BIOPHARMA
    * TIVIC HEALTH SYSTEMS INC - TO PAY STATERA $1.2 MILLION IN
EQUITY
AND $300,000 CASH FOR ENTOLIMOD

Source text:  ID:nBw6pThY2a 
Further company coverage:  TIVC.O 

 ((Reuters.Briefs@thomsonreuters.com;))